Couldn't find what you looking for?


Table of Contents

Oncolytic viruses for treatment of cancer are being developed for several decades already. But it seems that finally we are getting to the point when this technology can be successfully used in clinical practice.

Cancer is the second-leading cause of death in the United States; and although overall cancer death rates have declined due to advances in medicine and emergence of novel therapies, cancer is still one of the major causes of mortality around the globe. Despite aggressive multimodality treatments which include surgery, chemotherapy, and radiation therapy, deaths from aggressive cancer still persist and scientists have struggled for decades to develop more effective treatments.

The last decade has seen introduction of targeted anti-cancer therapeutics, specific drugs capable of killing certain types of cancer cells without affecting normal tissues and organs.

In some types of cancers, the improvements were very impressive. In many others, unfortunately, the situation changed very little. New, radically different approaches for cancer treatment are still needed. One of such approaches which attracts an increasing attention is viral therapy.

Viral therapy: old strategy with huge potential

Viral therapy, or oncolytic virotherapy, as it is usually referred to in scientific and medical circles, is one of the lesser known strategies, which has been under development for over 40 years now. The concept of eliminating cancer cells by using specific viral strains dates back to 1971, when a report was published describing the effects of the Newcastle disease virus in gastric cancer, which appeared to cause tumor regression following the infection of the cancerous cells. The connection between severe viral infections and tumor regression was noticed even earlier.

The principle underlying the action of oncolytic viruses is based on the fact that aggressive tumor cells show both impaired antiviral responses and optimal conditions for virus reproduction. 

The viruses can be manipulated and treated in many different ways and, as such, they can act as anticancer agents through a variety of mechanisms.

Some viruses have been artificially changed (“attenuated”) to predominantly replicate in and kill malignant cells while sparing normal tissues. Non-attenuated viruses that do not cause disease in humans can still effectively kill malignant cells in a similar fashion. Additionally, larger viruses can be armed to express immune-stimulating genes to recruit an influx of immune effector cells to further augment their therapeutic effect. Genetic manipulation of oncolytic viruses is particularly promising, as it offers much more complicated, gene-based therapeutics to be utilized to specifically target unique features of tumor cells. Therefore, these agents open up new horizons for the treatment of cancer types that commonly display poor prognosis.

When the general idea of using viruses to treat cancer first emerged, multiple preclinical studies were carried out with both tissue cultures and rodent disease models. Later on, hundreds of cancer patients were treated with impure oncolytic virus preparations (even infected body fluids) administered by almost every imaginable route. The viruses were usu­ally attacked by the patient’s own immune system and had little impact on tumor growth. However, in some cases the desired viral infection actually occurred and tumors regressed. However, investigations did not progress and much of the clinical studies on oncolytic therapy were halted until more recent years – mostly due to the fact that the adequate technology to carry out these investigations was not available.

Continue reading after recommendations

  • RUSSELL, S. J., PENG, K.-W. & BELL, J. C. 2012. Oncolytic virotherapy. Nature Biotechnology, 30, 1-13
  • AURELIAN, L. 2013. Oncolytic virotherapy: the questions and the promise. Oncolytic Virotherapy, 2, 19–29
  • MOEHLER, M., GOEPFERT, K., HEINRIC, B., BREITBACH, C. J., DELIC, M., GALLE, P. R. & ROMMELAERE, J. 2014. Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1. Frontiers in Oncology, 4, 92
  • RUSSELL, S. J., FEDERSPIEL, M. J., PENG, K.-W., TONG, C., DINGLI, D., MORICE, W. G., LOWE, V., O'CONNOR, M. K., KYLE, R. A., LEUNG, N., BUADI, F. K., RAJKUMAR, S. V., GERTZ, M. A., LACY, M. Q. & DISPENZIERI, A. 2014. Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings. Vol. 89 Iss. 5
  • SMITH, T. T., ROTH, J. C., FRIEDMAN, G. K. & GILLESPIE, G. Y. 2014. Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virotherapy, 3, 21-33
  • CHAI, Z., ZHANG, P., FU, F., ZHANG, X., LIU, Y., HU, L. & LI1, X. 2014. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer. Virology Journal, 11, 84.
  • Mindmap by
  • Photo courtesy of AJ Cann by Flickr :

Your thoughts on this

User avatar Guest